The Magazine for Sleep Professionals
Saturday, October 10, 2026
Frost & Sullivan is pleased to announce that SleepRes has been recognized with the 2026 North America New Product Innovation Recognition in the Positive Airway Pressure Devices industry for its outstanding achievements in product innovation, clinical differentiation, and patient-centric therapy design. This recognition highlights SleepRes’ leadership in advancing measurable clinical […]
sovaSage™ announced the new release of Clinical Indicator Intelligence™, an enhanced feature within sovaGuide™ featuring Jeanie™. Using machine learning, the new capability continuously analyzes multiple PAP therapy variables to help providers identify patients who may require additional clinical evaluation before therapy challenges lead to reduced benefit or treatment abandonment. The […]
LivaNova PLC announced the U.S. Food and Drug Administration (FDA) granted premarket approval (PMA) for the aura6000™ System for the treatment of adult patients with moderate to severe Obstructive Sleep Apnea (OSA). The System utilizes proximal hypoglossal nerve stimulation (p-HGNS), a differentiated neurostimulation modality, to treat OSA in patients with […]
ResMed launched its AirCurve 11 series devices, the company’s newest bilevel devices that use two levels of support, inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP), combined with digital technology to make it easier for healthcare providers to treat sleep apnea and to help patients start and […]
CPAP Supply Statement “With the announcement of the suspension of shipping of PAP devices by Philips Respironics, 3B Medical has put together guidance for companies ordering CPAP. As always, 3B Medical will always give first priority to customers that have supported the company over the long term. Starting last week and concluding […]
“Bilevel Rescue” study presented at SLEEP 2018 conference A new study reveals that shifting patients who are struggling with adherence to positive airway pressure (PAP) therapy to a more advanced bilevel device in the first 90 days of treatment is an effective tool for achieving adherence in well more than […]
